Merck partnership accelerates needle-free vaccine delivery

A University of Queensland invention that will deliver vaccines without the need for needles has struck a significant partnership with US-based pharmaceutical giant Merck, announced today.

The Nanopatch technology, which aims to replace the traditional needle and with a patch smaller than a postage stamp to deliver vaccines painlessly and more efficiently, will be licenced to Merck to begin commercial production on a vaccine.

UQ Vice-Chancellor Professor Peter Høj said the partnership accelerated the process of delivering the revolutionary health technology to people throughout the world.

"A major vaccine maker has looked at technologies around the world and chosen the UQ-invented Nanopatch," Professor Høj said.

"That is a tremendous credit to the team of researchers who developed the technology, led by Professor Mark Kendall.

"It also reflects the excellence of UQ's research , which ensures that practical, life-enhancing discoveries are made accessible to the people who need them.

"This link-up with Merck is especially inspiring, because it may lead to the relief of serious , particularly in remote and developing regions.

"In the immediate term, it will employ more people in Brisbane's innovation economy, and boost the global reputation of Queensland and Australian R&D."

The Nanopatch technology, now being developed by privately held biotechnology company Vaxxas, originated from Vaxxas Chief Technology Officer Professor Mark Kendall's research group at UQ's Australian Institute for Bioengineering and Nanotechnology.

"It is exciting to commence this important partnership between Vaxxas and Merck – a big step forward towards the Nanopatch becoming a vaccine delivery product," Professor Kendall said.

"This directly builds upon intensive and outstanding research on the Nanopatch – conducted by my research group at UQ – taking the Nanopatch from an idea to achieving unprecedented immune responses in animals. And our research has been supported by competitive research grants from both the Australian and Queensland State Governments."

Through the Merck partnership, Vaxxas will be eligible to receive payments for up to two additional vaccines developed by Merck using the Nanopatch platform, as well as milestone payments on Merck vaccine development and regulatory approvals, and royalties on sales of any vaccines that ultimately use the Nanopatch platform.

The Nanopatch works through thousands of small projections designed to deliver a to abundant immune cells in the skin, whereas the traditional syringe delivers to the muscle, where there are few immune cells.

Nanopatch delivery can improve the efficiency of vaccines—including achieving protection against influenza—with only 1/100th of the dose used with a needle and syringe.

The Nanopatch has the potential to improve patient convenience, reduce needle-stick injuries and overcome cross contamination.

It is designed for thermostability and may not need refrigeration, potentially making transport much cheaper and easier, particularly to developing nations.

add to favorites email to friend print save as pdf

Related Stories

Nanopatches to join the fight against swine flu

Jul 14, 2009

In response to the growing threat of swine flu, a UQ team is applying nanopatch technology to potentially solve the problems associated with vaccinating millions of Australians, thanks to a recently announced government grant.

'Nanopatches' to replace needles

Apr 11, 2006

People who fear needles may one day have no need to fear the doctor, with the help of a funding injection for The University of Queensland's Professor Mark Kendall.

Recommended for you

Study recalculates costs of combination vaccines

Apr 17, 2014

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive ...

Drug watchdog urges vigilance in cancer drug theft

Apr 17, 2014

Europe's medicine watchdog urged doctors Thursday to be vigilant in administering the cancer drug Herceptin, vials of which had been stolen in Italy and tampered with before being sold back into the supply chain.

User comments